100
Participants
Start Date
September 30, 2009
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
CS7017
CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
Oncosalud SAC, Lima
John Marshall, Washington D.C.
Victor Priego, Bethesda
Georgia Cancer Specialists, Atlanta
Gabrail Cancer Center, Canton
Beverly Hills Cancer Center, Beverly Hills
St. Jude Heritage Medical Group, Fullerton
Instituto Oncologico Clinica Renaca, Viña del Mar
Fundacion Arturo Lopez Perez, Santiago
Instituto Nacional del Cancer, Santiago
Instituto FIDES Oncologia y Especialidades Medicas, Buenos Aires
CAIPO Centro para la Atencion Integral del Paciente Oncologico, San Miguel de Tucumán
Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul - PUC-RS, Porto Alegre
Instituto Nacional de Cancer INCA, Rio de Janeiro
ICAVC, São Paulo
Hospital Nacional Alberto Sabogai Sologuren, Callao
Hospital Nacional Dos de Mayo, Lima
Hospital Nacional Dos de Mayo, Lima
Lead Sponsor
Daiichi Sankyo
INDUSTRY